RIGL
Rigel Pharmaceuticals Inc
48.20$
+0.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -845.5% | -81.0% | -372.3% | -1,729.6% | -132.2% | -70.0% | -48.0% | 3.9% | -61.3% | -4.9% | 17.6% | 25.7% | |
| 28.6% | 5.0% | 4.6% | 10.4% | 1.3% | 1.2% | 0.6% | 0.8% | 0.8% | 1.1% | 1.2% | 0.8% | |
| 118.6% | 25.6% | 36.0% | 133.5% | 17.3% | 15.4% | 6.7% | 6.4% | 10.3% | 7.5% | 6.9% | 4.3% | |
| 117.4% | 25.4% | 39.6% | 117.2% | 17.3% | 15.4% | 6.7% | 8.7% | 10.9% | – | – | – | |
| -2.4% | 66.7% | -77.5% | -121.1% | 9.3% | 28.1% | -27.9% | 6.5% | -24.2% | 8.1% | 0.1% | -6.6% | |
| 5.0% | 1.9% | 3.9% | 3.7% | 2.5% | 2.5% | 1.2% | 0.4% | 0.4% | 12.8% | 0.2% | 0.0% | |
| 762.8% | 154.4% | 122.1% | -434.3% | 56.1% | -39.9% | 43.7% | -53.6% | 60.5% | -3.7% | 2.3% | -31.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 14.2% | 24.4% | 123.6% | 2,624.6% | 161.5% | 2.7% | 2.4% | 3.2% | 1.8% | 0.0% | -5.6% | 0.0% | |
| – | – | 48.0% | 218.3% | 22.0% | 16.5% | 9.2% | 13.1% | 16.3% | 17.1% | 0.0% | -2.5% | |
| 14.2% | 24.4% | 123.6% | 2,624.6% | 161.5% | 19.2% | 11.6% | 42.0% | 5.4% | 15.7% | -6.5% | 0.2% | |
| -68.5% | 97.8% | -126.7% | 460.7% | 85.4% | -90.7% | 7.2% | -7.7% | 4.6% | 7.1% | 13.4% | -5.5% | |
| -850.5% | -82.9% | -376.3% | -1,733.3% | -134.7% | -72.5% | -49.2% | 3.5% | -61.7% | -17.7% | 17.3% | 25.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.